0N6A Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
TME Pharma N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.12 |
| 52 Week High | €0.58 |
| 52 Week Low | €0.09 |
| Beta | 1.77 |
| 11 Month Change | -4.45% |
| 3 Month Change | -8.26% |
| 1 Year Change | -76.92% |
| 33 Year Change | -99.53% |
| 5 Year Change | -99.68% |
| Change since IPO | -99.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0N6A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.9% | -1.3% | 0.02% |
| 1Y | -76.9% | -11.5% | 19.6% |
Return vs Industry: 0N6A underperformed the German Biotechs industry which returned -11.5% over the past year.
Return vs Market: 0N6A underperformed the German Market which returned 19.6% over the past year.
Price Volatility
| 0N6A volatility | |
|---|---|
| 0N6A Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0N6A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0N6A's weekly volatility has decreased from 17% to 11% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 13 | Aram Mangasarian | www.tmepharma.com |
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. The company is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy.
TME Pharma N.V. Fundamentals Summary
| 0N6A fundamental statistics | |
|---|---|
| Market cap | €5.76m |
| Earnings (TTM) | -€6.32m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs 0N6A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0N6A income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €6.33m |
| Earnings | -€6.32m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0N6A perform over the long term?
See historical performance and comparison